1261398-44-0

1261398-44-0 structure

Name: Pazopanib-13C,d3 hydrochloride
Chemical Name: 5-[(4-{(2,3-Dimethyl-2H-indazol-6-yl)[(13C,2H3)methyl]amino}-2-pyrimidinyl)amino]-2-methylbenzenesulfonamide hydrochloride (1:1)
CAS Number: 1261398-44-0
Molecular Formula: C₂₀₁₃CH₂₁D₃ClN₇O₂S
Molecular Weight: 477.990
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2018-07-04 18:12:44
Modify Date: 2024-01-13 18:49:29
Pazopanib-13C,d3 (hydrochloride) is the deuterium and 13C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

Name	5-[(4-{(2,3-Dimethyl-2H-indazol-6-yl)[(13C,2H3)methyl]amino}-2-pyrimidinyl)amino]-2-methylbenzenesulfonamide hydrochloride (1:1)
Synonyms	Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methyl-13C-d3-amino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1) 5-[(4-{(2,3-Dimethyl-2H-indazol-6-yl)[(13C,2H3)methyl]amino}-2-pyrimidinyl)amino]-2-methylbenzenesulfonamide hydrochloride (1:1)

Description	Pazopanib-13C,d3 (hydrochloride) is the deuterium and 13C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Fms Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Harris PA, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008, 51(15), 4632-4640. [3]. Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov82(3):346-50.

Molecular Formula	C₂₀₁₃CH₂₁D₃ClN₇O₂S
Molecular Weight	477.990
Exact Mass	477.162262

1261398-44-0	1261734-88-6
1261394-10-8	1216630-06-6
1261397-71-0	1329612-87-4
1261392-55-5	2747918-20-1
2126178-55-8	1189508-77-7
1158522-08-7	940364-43-2
134104-43-1	1270482-77-3
131615-57-1	1280803-70-4
6906-52-1	930439-75-1
1018584-77-4	1351607-55-0